Eradykacja Helicobacter pylori – co wynika z nowych wytycznych Polskiego Towarzystwa Gastroenterologii Artykuł przeglądowy
##plugins.themes.bootstrap3.article.main##
Abstrakt
Infekcja Helicobacter pylori stanowi ogólnoświatowy problem w związku ze znaczącą chorobowością oraz śmiertelnością wtórnie do choroby wrzodowej oraz nowotworów żołądka. W 2023 r. Grupa Robocza Polskiego Towarzystwa Gastroenterologii opublikowała rekomendacje dotyczące diagnostyki i leczenia Helicobacter pylori. Dokument ten uaktualnia dotychczasowe rekomendacje z 2014 r.
Rekomendacje skupiają się na praktycznych aspektach zakażenia H. pylori, określają wskazania do diagnostyki oraz leczenia, omawiają rekomendowane algorytmy leczenia.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Przybylska-Feluś, M., & Zwolińska-Wcisło, M. (2023). Eradykacja Helicobacter pylori – co wynika z nowych wytycznych Polskiego Towarzystwa Gastroenterologii . Medycyna Faktów , 16(4(61), 290-294. https://doi.org/10.24292/01.MF.0423.01
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Malfertheiner P, Megraud F, Rokkas T et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022; 71: 1724-62.
2. Jaroń K, Pietrzak A, Daniluk J et al. Diagnostic and therapeutic recommendations on Helicobacter pylori infection. Recommendations of the working group of the Polish Society of Gastroenterology. Gastroenterology Rev. 2023; 18(3): 225-48.
3. Kotilea K, Bontems P, Touati E. Epidemiology, Diagnosis and Risk Factors of Helicobacter pylori Infection. Adv Exp Med Biol. 2019; 1149: 17-33.
4. Hanafiah A, Lopes BS. Genetic diversity and virulence characteristics of Helicobacter pylori isolates in different human ethnic groups. Infect Genet Evol. 2020; 78: 104135.
5. Jones NL, Koletzko S, Goodman K et al. ESPGHAN, NASPGHAN. Joint ESPGHAN/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents (update 2016). J Pediatr Gastroenterol Nutr. 2017; 64(6): 991-1003.
6. Muhammad JM, Sugiyama T, Zaidi SF. Gastric pathophysiological ins and outs of helicobacter pylori: a review. J Pak Med Assoc. 2013; 63(12): 1528–33.
7. Sugimoto M, Yamaoka Y, Shirai N et al. Role of renin-angiotensin system in gastric oncogenesis. J Gastroenterol Hepatol. 2012; 27(3): 442-51.
8. Chojnacki C, Konrad P, Błońska A et al. Usefulness of the hydrogen breath test in patients with functional dyspepsia. Prz Gastroenterol. 2020; 15(4): 338-42.
9. Konrad P, Chojnacki J, Gąsiorowska A et al. Therapeutic efficacy of amoxicillin and rifaximin in patients with small intestinal bacterial overgrowth and Helicobacter pylori infection. Prz Gastroenterol. 2018; 13(3): 213-17.
10. Dharan M, Wozny D Helicobacter pylori infection and small intestinal bacterial overgrowth-more than what meets the eye. World J Clin Cases. 2022; 10(21): 7209-14.
11. Balamtekin N, Cumhur Artuk C et al. The effect of Helicobacter pylori on the presentation and clinical course of coronavirus disease 2019 infection. J Pediatr Gastroenterol Nutr. 2021; 72(4): 511-13.
12. World Gastroenterology Organisation: Global guidelines Helicobacter pylori. 2021.
13. Ding S-Z, Du Y-Q, Lui H et al. Chinese consensus report on family-based helicobacter pylori infection control and management (2021 edition). Gut. 2022; 71(2): 238-53.
14. Ferenc S, Gnus J, Kościelna M et al. High antibiotic resistance of Helicobacter pylori and its effect on tailored and empiric eradication of the organism in Lower Silesia, Poland. Helicobacter. 2017; 22(2): e12365.
15. Nyssen OP, Perez‐Aisa A, Castro‐Fernandez M et al. European Registry on Helicobacter pylori management: Single‐capsule bismuth quadruple therapy is effective in real‐world clinical practice. United European Gastroenterol J. 2021; 9(1): 38-46.
16. Lee M, Kemp JA, Canning A et al. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med.1999; 159(19): 2312-6.
17. Dąbrowski A, Hartleb M, Nowakowska-Duława E et al. (ed). Choroby układu pokarmowego. In: Interna Szczeklika – Podręcznik chorób wewnętrznych. Medycyna Praktyczna, Kraków 2022.
2. Jaroń K, Pietrzak A, Daniluk J et al. Diagnostic and therapeutic recommendations on Helicobacter pylori infection. Recommendations of the working group of the Polish Society of Gastroenterology. Gastroenterology Rev. 2023; 18(3): 225-48.
3. Kotilea K, Bontems P, Touati E. Epidemiology, Diagnosis and Risk Factors of Helicobacter pylori Infection. Adv Exp Med Biol. 2019; 1149: 17-33.
4. Hanafiah A, Lopes BS. Genetic diversity and virulence characteristics of Helicobacter pylori isolates in different human ethnic groups. Infect Genet Evol. 2020; 78: 104135.
5. Jones NL, Koletzko S, Goodman K et al. ESPGHAN, NASPGHAN. Joint ESPGHAN/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents (update 2016). J Pediatr Gastroenterol Nutr. 2017; 64(6): 991-1003.
6. Muhammad JM, Sugiyama T, Zaidi SF. Gastric pathophysiological ins and outs of helicobacter pylori: a review. J Pak Med Assoc. 2013; 63(12): 1528–33.
7. Sugimoto M, Yamaoka Y, Shirai N et al. Role of renin-angiotensin system in gastric oncogenesis. J Gastroenterol Hepatol. 2012; 27(3): 442-51.
8. Chojnacki C, Konrad P, Błońska A et al. Usefulness of the hydrogen breath test in patients with functional dyspepsia. Prz Gastroenterol. 2020; 15(4): 338-42.
9. Konrad P, Chojnacki J, Gąsiorowska A et al. Therapeutic efficacy of amoxicillin and rifaximin in patients with small intestinal bacterial overgrowth and Helicobacter pylori infection. Prz Gastroenterol. 2018; 13(3): 213-17.
10. Dharan M, Wozny D Helicobacter pylori infection and small intestinal bacterial overgrowth-more than what meets the eye. World J Clin Cases. 2022; 10(21): 7209-14.
11. Balamtekin N, Cumhur Artuk C et al. The effect of Helicobacter pylori on the presentation and clinical course of coronavirus disease 2019 infection. J Pediatr Gastroenterol Nutr. 2021; 72(4): 511-13.
12. World Gastroenterology Organisation: Global guidelines Helicobacter pylori. 2021.
13. Ding S-Z, Du Y-Q, Lui H et al. Chinese consensus report on family-based helicobacter pylori infection control and management (2021 edition). Gut. 2022; 71(2): 238-53.
14. Ferenc S, Gnus J, Kościelna M et al. High antibiotic resistance of Helicobacter pylori and its effect on tailored and empiric eradication of the organism in Lower Silesia, Poland. Helicobacter. 2017; 22(2): e12365.
15. Nyssen OP, Perez‐Aisa A, Castro‐Fernandez M et al. European Registry on Helicobacter pylori management: Single‐capsule bismuth quadruple therapy is effective in real‐world clinical practice. United European Gastroenterol J. 2021; 9(1): 38-46.
16. Lee M, Kemp JA, Canning A et al. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med.1999; 159(19): 2312-6.
17. Dąbrowski A, Hartleb M, Nowakowska-Duława E et al. (ed). Choroby układu pokarmowego. In: Interna Szczeklika – Podręcznik chorób wewnętrznych. Medycyna Praktyczna, Kraków 2022.